

ASX release

7 September 2026

Change of Director's Interest – David Koczkar

In accordance with the Listing Rules, Medibank attaches an Appendix 3Y – Change of Director's Interest Notice for David Koczkar for release to the market.

This document has been authorised for release by Ashley Spencer, General Counsel – Health, Governance & Excellence Hubs.

For further information please contact:

For media

Emily Ritchie
Senior Executive, External Affairs
M: +61 429 642 418
E: Emily.Ritchie@medibank.com.au

For investors/analysts

Colette Campbell
Senior Executive, Investor Relations
M: +61 475 975 770
E: Investor.Relations@medibank.com.au

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity: MEDIBANK PRIVATE LIMITED
ABN: 47 080 890 259

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	David Koczkar
Date of last notice	29 December 2025

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct (Performance Rights pursuant to the Medibank Private Limited Performance Rights Plan (' <i>Performance Rights Plan</i> '))
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	
Date of change	1 September 2026
No. of securities held prior to change	2,275,601 Performance Rights, being: • 653,088 Performance Rights granted under the FY24 Long Term Incentive (<i>LTI</i>); • 139,737 Performance Rights granted under the FY24 Deferred Short Term Incentive (<i>Deferred STI</i>); • 758,130 Performance Rights granted under the FY25 LTI; • 132,180 Performance Rights granted under the FY25 Deferred STI; and • 592,466 Performance Rights granted under the FY26 LTI.
Class	Performance Rights

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Number acquired	Nil
Number disposed	223,973 Performance Rights, being: • 34,934 exercised Performance Rights granted under the FY24 Deferred STI; and • 26,436 exercised Performance Rights granted under the FY25 Deferred STI, in each case converted to ordinary shares in Medibank Private Limited (<i>Ordinary Shares</i>) as set out below; and • 162,603 lapsed Performance Rights granted under the FY24 LTI.
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Performance Rights are granted at nil consideration under the terms of the Performance Rights Plan.
No. of securities held after change	2,051,628 Performance Rights, being: • 490,485 Performance Rights granted under the FY24 LTI; • 104,803 Performance Rights granted under the FY24 Deferred STI; • 758,130 Performance Rights granted under the FY25 LTI; • 105,744 Performance Rights granted under the FY25 Deferred STI; and • 592,466 Performance Rights granted under the FY26 LTI.
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Exercising and lapsing of Performance Rights under the Performance Rights Plan

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Indirect interest in Ordinary Shares held via Olive Man Investments Pty Ltd
Date of change	1 September 2026
No. of securities held prior to change	2,420,503 Ordinary Shares (indirect).
Class	Ordinary Shares

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Number acquired	65,073 Ordinary Shares (direct), being: • 34,934 Ordinary Shares following exercise of 34,934 Performance Rights granted under the FY24 Deferred STI; • 26,436 Ordinary Shares following exercise of 26,436 Performance Rights granted under the FY25 Deferred STI; and • 3,703 Ordinary Shares, being the number of Ordinary Shares having an equivalent value to the dividends that would have been received during the relevant deferral period if Ordinary Shares were held instead of the Performance Rights granted under the FY24 Deferred STI and FY25 Deferred STI.
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Acquisition of Ordinary Shares pursuant to exercise of Performance Rights under the Performance Rights Plan for no consideration
No. of securities held after change	2,485,576 Ordinary Shares, being: • 65,073 Ordinary Shares (direct); • 2,420,503 Ordinary Shares (indirect).
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Acquisition of Ordinary Shares pursuant to exercise of Performance Rights under the Performance Rights Plan.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺ closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.